Payment overview · 2025
General Payments
$24.78
1 reported records · 1 companies
Healthcare provider profile · identity verified
Jason M Nitke, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · DE PERE, WI · NPI 1629026059
Verified facts
What the public records show
CMS Open Payments records show Jason M Nitke, D.O. received $24.78 in general payments during 2025 across 1 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.78 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $24.78 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABILIFY Normalized: abilify |
Drug | E.R. Squibb & Sons, L.L.C. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
130 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1042 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 571 | 154 |
| Losartan Potassium | Losartan Potassium | 438 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 433 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 363 | 97 |
| Lisinopril | Lisinopril | 355 | 98 |
| Omeprazole | Omeprazole | 316 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 75 |
| Gabapentin | Gabapentin | 247 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 63 |
| Mounjaro | Tirzepatide | 193 | 36 |
| Metformin Hcl | Metformin Hcl | 192 | 52 |
| Allopurinol | Allopurinol | 188 | 46 |
| Warfarin Sodium | Warfarin Sodium | 171 | 34 |
| Jardiance | Empagliflozin | 167 | 39 |
| Metformin Hcl Er | Metformin Hcl | 163 | 43 |
| Sertraline Hcl | Sertraline Hcl | 152 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 146 | 41 |
| Furosemide | Furosemide | 142 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 40 |
| Simvastatin | Simvastatin | 138 | 39 |
| Trazodone Hcl | Trazodone Hcl | 136 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 50 |
| Finasteride | Finasteride | 135 | 36 |
| Eliquis | Apixaban | 130 | 30 |
| Glimepiride | Glimepiride | 126 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 120 | 35 |
| Carvedilol | Carvedilol | 118 | 34 |
| Tramadol Hcl | Tramadol Hcl | 115 | 23 |
| Alprazolam | Alprazolam | 109 | 29 |
| Atenolol | Atenolol | 107 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 36 |
| Chlorthalidone | Chlorthalidone | 98 | 29 |
| Bupropion Xl | Bupropion Hcl | 97 | 22 |
| Clonazepam | Clonazepam | 97 | 16 |
| Potassium Chloride | Potassium Chloride | 97 | 25 |
| Celecoxib | Celecoxib | 96 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 31 |
| Meloxicam | Meloxicam | 92 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 25 |
| Famotidine | Famotidine | 82 | 25 |
| Lorazepam | Lorazepam | 79 | 18 |
| Spironolactone | Spironolactone | 76 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 70 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 16 |
| Prednisone | Prednisone | 68 | 47 |
| Pregabalin | Pregabalin | 67 | 16 |
| Xarelto | Rivaroxaban | 67 | 19 |
| Alendronate Sodium | Alendronate Sodium | 64 | 20 |
| Diazepam | Diazepam | 64 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 17 |
| Donepezil Hcl | Donepezil Hcl | 61 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 18 |
| Ozempic | Semaglutide | 59 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 56 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 53 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 51 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 16 |
| Mirtazapine | Mirtazapine | 48 | 14 |
| Glipizide | Glipizide | 47 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Torsemide | Torsemide | 44 | 14 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 43 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Risperidone | Risperidone | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 14 |
| Ezetimibe | Ezetimibe | 37 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 11 |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Testosterone | Testosterone | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 15 |
| Temazepam | Temazepam | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 25 |
| Valsartan | Valsartan | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | 11 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Niacin Er | Niacin | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 12 |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Nystatin | Nystatin | 15 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 14 |
| Glipizide Er | Glipizide | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Baclofen | Baclofen | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Euthyrox | Levothyroxine Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $24.78 · 1 records | E.R. Squibb & Sons, L.L.C. | ABILIFY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error